^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

538P - Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

Published date:
09/14/2020
Excerpt:
Antitumor activity of vemurafenib was important in V600-mutated NSCLC, HCL, sarcoma, ovarian cancer, brain tumors, histiocytosis and gangliogliomas. Importantly, Non-V600 mutated tumors derived no benefit….Table: 538P
Trial ID:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

Excerpt:
Patients with BRAFV600-mutant glioma received vemurafenib 960 mg twice per day continuously...Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including...anaplastic ganglioglioma (n = 3), pilocytic astrocytoma (n = 2), and high-grade glioma, not otherwise specified (n = 1), were treated....Responses among patients with other tumor types included PR in one patient with PA who was treated for 15.3 months and PR in one patient with AGG who was treated for 13.8 months for a confirmed clinical benefit rate of 33% (95% CI, 4.3% to 77.7%).
DOI:
10.1200/JCO.2018.78.9990
Trial ID: